A genetically engineered probiotic bacterium successfully delivered a therapeutic anti-inflammatory peptide orally, dramatically reducing rheumatoid arthritis symptoms in rats.
Oral peptide delivery achievedA single oral dose of the engineered probiotic delivered enough functional peptide to the bloodstream to reduce inflammation in rats.
What the researchers found
Researchers engineered a probiotic bacterium (Lactobacillus reuteri) to produce and secrete ShK-235, a peptide that blocks the Kv1.3 potassium channel on inflammatory T cells. When fed to rats, a single oral dose delivered enough functional peptide into the bloodstream to reduce skin inflammation, and daily oral dosing dramatically reduced disease severity in a rat model of rheumatoid arthritis. The peptide did not trigger an immune response against itself, suggesting the probiotic delivery approach avoids the immunogenicity problems that plague many injected peptide drugs.
Why it matters
This study solves two major problems at once: oral delivery of a peptide (normally impossible because the gut destroys peptides) and targeted immunosuppression without broad immune shutdown. Using a probiotic as a living factory that continuously produces a therapeutic peptide in the gut is a creative approach that could transform how autoimmune diseases are treated — replacing daily injections with a simple oral dose.
How the study worked
The team genetically engineered L. reuteri to secrete the Kv1.3-blocking peptide ShK-235 on demand. They verified the secreted peptide blocked Kv1.3 channels and selectively inhibited inflammatory T cell proliferation in cell cultures. In rats, they tested single and daily oral doses against two disease models: delayed-type hypersensitivity (atopic dermatitis model) and a rheumatoid arthritis model, measuring clinical disease scores, joint inflammation, and anti-peptide antibody responses.
Who was studied
Rats (delayed-type hypersensitivity and rheumatoid arthritis models) and human T cells (in vitro)
What this study cannot tell us
This is an animal study in rats — translation to humans faces significant hurdles including regulatory approval of genetically modified probiotics, differences in human vs rat gut environments, and the need to verify adequate peptide absorption in humans. Long-term safety of colonization with engineered bacteria is unknown. The specific rat disease models don't perfectly replicate human rheumatoid arthritis.
How to read the evidence
This is preliminary-grade evidence from an animal study, but published in the high-impact journal PNAS. The in vitro and in vivo data are compelling, but human translation remains unproven.
When this study was published
Published in 2023. This is recent and represents a cutting-edge approach to oral peptide delivery. Watch for follow-up studies testing this platform in larger animals or early human trials.
The bigger picture
This study sits at the intersection of three hot fields: engineered probiotics, peptide therapeutics, and autoimmune disease. The concept of using living bacteria as drug factories in the gut is gaining traction, with multiple companies developing similar approaches for other diseases. If this platform works in humans, it could make peptide therapies accessible as simple oral products — no injections, no refrigeration, no absorption enhancers needed.
Questions still open
- Will the engineered probiotic colonize the human gut effectively enough to deliver therapeutic peptide levels?
- How will regulatory agencies evaluate genetically modified probiotics as drug delivery vehicles?
- Could this probiotic delivery platform be adapted for other therapeutic peptides beyond ShK-235?
Common questions
How does a probiotic deliver a peptide drug?
What is Kv1.3 and why does blocking it help rheumatoid arthritis?
Read the original research
A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.
Proceedings of the National Academy of Sciences of the United States of America, 120(2), e2211977120
Citation
Wang, Yuqing; Zhu, Duolong; Ortiz-Velez, Laura C; Perry, Jacob L; Pennington, Michael W; Hyser, Joseph M; Britton, Robert A; Beeton, Christine. (2023). A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.. Proceedings of the National Academy of Sciences of the United States of America, 120(2), e2211977120. https://doi.org/10.1073/pnas.2211977120